Department of Clinical Pharmacology, Institute of Clinical and Experimental Pharmacology and Toxicology, University Hospital of Tuebingen, Tuebingen, Germany.
PLoS One. 2013 Oct 4;8(10):e77182. doi: 10.1371/journal.pone.0077182. eCollection 2013.
Extracellular accumulation of toxic concentrations of glutamate (Glu) is a hallmark of many neurodegenerative diseases, often accompanied by hypoxia and impaired metabolism of this neuromediator. To address the question whether the multifunctional neuroprotective action of erythropoietin (EPO) extends to the regulation of extracellular Glu-level and is age-related, young and culture-aged rat astroglial primary cells (APC) were simultaneously treated with 1mM Glu and/or human recombinant EPO under normoxic and hypoxic conditions (NC and HC). EPO increased the Glu uptake by astrocytes under both NC and especially upon HC in culture-aged APC (by 60%). Moreover, treatment with EPO up-regulated the activity of glutamine synthetase (GS), the expression of glutamate-aspartate transporter (GLAST) and the level of EPO mRNA. EPO alleviated the Glu- and hypoxia-induced LDH release from astrocytes. These protective EPO effects were concentration-dependent and they were strongly intensified with age in culture. More than a 4-fold increase in apoptosis and a 2-fold decrease in GS enzyme activity was observed in APC transfected with EPO receptor (EPOR)-siRNA. Our in vivo data show decreased expression of EPO and a strong increase of EPOR in brain homogenates of APP/PS1 mice and their wild type controls during aging. Comparison of APP/PS1 and age-matched WT control mice revealed a stronger expression of EPOR but a weaker one of EPO in the Alzheimer's disease (AD) model mice. Here we show for the first time the direct correlation between the extent of differentiation (age) of astrocytes and the efficacy of EPO in balancing extracellular glutamate clearance and metabolism in an in-vitro model of hypoxia and Glu-induced astroglial injury. The clinical relevance of EPO and EPOR as markers of brain cells vulnerability during aging and neurodegeneration is evidenced by remarkable changes in their expression levels in a transgenic model of AD and their WT controls.
细胞外谷氨酸(Glu)浓度升高是许多神经退行性疾病的标志,常伴有缺氧和这种神经递质代谢受损。为了探讨促红细胞生成素(EPO)的多功能神经保护作用是否扩展到调节细胞外 Glu 水平以及是否与年龄相关,我们同时用 1mM Glu 和/或重组人 EPO 处理年轻和培养老化的大鼠星形胶质细胞原代细胞(APC),在常氧和低氧条件下(NC 和 HC)。EPO 在 NC 下,特别是在培养老化的 APC 下的 HC 下,增加了星形胶质细胞对 Glu 的摄取(增加了 60%)。此外,EPO 处理上调了谷氨酰胺合成酶(GS)的活性、谷氨酸-天冬氨酸转运体(GLAST)的表达和 EPO mRNA 的水平。EPO 减轻了 Glu 和缺氧诱导的星形胶质细胞内乳酸脱氢酶(LDH)的释放。这些保护作用依赖于 EPO 的浓度,并且在培养中随年龄的增长而显著增强。在转染了 EPO 受体(EPOR)-siRNA 的 APC 中,观察到凋亡增加了 4 倍以上,GS 酶活性降低了 2 倍。我们的体内数据显示,APP/PS1 小鼠及其野生型对照在衰老过程中脑匀浆中 EPO 的表达减少,而 EPOR 的表达增加。APP/PS1 与年龄匹配的 WT 对照小鼠的比较显示,AD 模型小鼠中 EPOR 的表达更强,而 EPO 的表达更弱。在这里,我们首次在缺氧和 Glu 诱导的星形胶质细胞损伤的体外模型中显示了星形胶质细胞分化程度(年龄)与 EPO 平衡细胞外谷氨酸清除和代谢的功效之间的直接相关性。EPO 和 EPOR 作为衰老和神经退行性变过程中脑细胞易损性的标志物的临床相关性,通过它们在 AD 转基因模型及其 WT 对照中的表达水平的显著变化得到了证实。